The Brain’s Silent Partnership: How Astrocytes and Microglia Talk From Birth to Disease

Deep inside the brain, two cell types that could not be more different in origin spend their entire lives in constant conversation. Astrocytes, the star-shaped support cells born from the same neural lineage as neurons, and microglia, the brain’s resident immune cells descended from yolk-sac macrophages, form one of the most consequential yet underappreciated partnerships in neuroscience. A new review published in Frontiers in Network Physiology by Alberto Javier Ramos and Alejandro Villarreal of the University of Buenos Aires and the Instituto Tecnológico de Buenos Aires synthesizes decades of evidence showing that this astrocyte–microglia crosstalk begins during embryonic development, sustains the healthy adult brain, and, when it goes wrong, drives the self-amplifying inflammation that underlies Alzheimer’s disease, stroke, epilepsy, and traumatic brain injury.

The review’s most striking finding is not biological but bibliographic. When the authors systematically searched PubMed for studies directly addressing astrocyte–microglia communication, they found a dramatic imbalance: only 28 records addressed crosstalk during development, 94 during adult homeostasis, and a staggering 1,554 in pathological contexts. This skew, the authors argue, reflects both technical and conceptual biases. Studying two cell types talking to each other in a healthy brain is extraordinarily difficult because most experimental interventions—cell depletion, inflammatory stimulation, genetic manipulation—themselves perturb the system and trigger the very reactive states researchers are trying to avoid. Pathology, by contrast, makes the conversation loud enough to hear.

The story begins before birth. Microglia are the first glial cells to arrive in the developing brain, colonizing it from hematopoietic stem cells in the yolk sac around the fourth gestational week in humans and before embryonic day 8 in mice. Astrocytes, generated later from radial glial neural progenitors after the peak of neurogenesis, enter a brain already populated by these early immune sentinels. That timing matters. In vitro work with neural progenitor cells has shown that microglia-derived factors such as interleukin 6 (IL-6) and leukemia inhibitory factor (LIF) promote astrocyte differentiation, and microglial phagocytosis of newly born cells may help regulate final neuron and astrocyte numbers. In other words, the immune cells that arrive first may help shape the identity and abundance of the glial cells that follow.

As the brain matures, the direction of influence reverses. During spinal cord development, astrocytes secrete IL-33, which acts on microglia to promote synapse engulfment—the process by which excess connections are pruned to sculpt functional neural circuits. In the postnatal cortex, microglia instruct astrocytes through Wnt signaling to disengage synapses before microglia consume them. And in the developing thalamus, astrocytes signal to microglia through interactions between the protein Hevin and Toll-like receptor 4, boosting microglial phagolysosomal activity and synapse removal. These findings reveal a genuinely bidirectional dialogue: microglia first shepherd astrocyte differentiation, then mature astrocytes reciprocate by directing microglial pruning. Disruption of this choreography during critical developmental windows has been implicated in schizophrenia and autism spectrum disorders.

In the healthy adult brain, both cell types are indispensable guardians of homeostasis. Astrocytes metabolically couple to neurons through the lactate shuttle, wrap around synapses to regulate glutamate via transporters such as EAAT2 and EAAT1, buffer potassium to link neuronal firing with blood flow, form gap-junction-coupled syncytia through connexins that integrate activity across broad brain regions, and maintain the blood–brain barrier and water balance through aquaporin 4 channels. Microglia, meanwhile, continuously survey the parenchyma with motile processes, regulate synaptic function, and maintain myelin integrity after developmental ensheathment. Yet the review emphasizes that how these two cells regulate each other under physiological conditions remains poorly understood—many of the inferred interactions come from studies that used proinflammatory stimuli, which likely mimic disease rather than health.

What evidence does exist for homeostatic crosstalk is intriguing. Microglia release trophic and immunomodulatory mediators including transforming growth factor β (TGF-β), IL-10, and insulin-like growth factor 1, which can restrain astrocytic inflammatory responses. Astrocytes and microglia coordinate phagocytosis of neuronal corpses through MERTK-dependent pathways, and astrocytes can even clear microglial debris via complement component 4b–mediated phagocytosis—a process important for microglial turnover in vivo. Pharmacological depletion of microglia causes astrocyte syncytium uncoupling through downregulation of connexins 30 and 43 in the mouse hippocampus, suggesting that microglia actively maintain the astrocyte network itself. These observations hint that the healthy brain’s stability depends on a continuous glial dialogue that science has barely begun to map.

When injury or disease strikes, that dialogue turns dark. Microglia, the first responders to central nervous system damage, release tumor necrosis factor α, IL-1α, and complement component C1q, which synergistically push astrocytes into inflammatory reactive states characterized by impaired homeostatic functions and secretion of neurotoxic molecules. Reactive astrocytes then amplify the cycle by releasing IL-6, GM-CSF, chemokines such as CCL2 and CXCL10, complement proteins, ATP, and damage-associated molecular patterns, sustaining leukocyte recruitment and chronic neuroinflammation. The review’s authors, who have studied this axis experimentally, showed that NF-κB activation in astrocytes is enhanced in cultures with high microglial density and is microglia-dependent in vivo models of inflammation. STAT3 activation in reactive astrocytes at injury borders also depends on microglia, linking the immune cells directly to scar formation dynamics.

Perhaps the most conceptually provocative idea in the review is that pathology reactivates developmental programs. The complement cascade—C1q, C3, and their receptors—orchestrates synaptic pruning during development but drives aberrant synapse elimination in neurodegeneration. In stroke models, astrocytes at injury borders appear to express C3, potentially recruiting C3aR-expressing microglia; in Alzheimer’s disease models, the C3–C3aR pathway mediates both amyloid-beta clearance and neurotoxic inflammation. Similarly, IL-33–ST2 signaling, TGF-β signaling, CSF-1/IL-34–CSF1R, CX3CL1–CX3CR1, purinergic ATP signaling through P2Y12 and P2X7, and the TREM2–ApoE axis all appear redeployed in disease, where their sustained activation promotes maladaptive crosstalk, perpetuating neuroinflammation and progressive neuronal damage. Pathological crosstalk, the authors conclude, is not mediated by a single pathway but by the coordinated reactivation of multiple developmental communication programs.

Studying this partnership has always been methodologically hard, and the review surveys both traditional and emerging tools. Classic approaches—histological correlation, cell-type-specific genetic manipulation with GFAP or ALDH1L1 promoters, pharmacological microglial depletion via CSF1R inhibitors, astrocyte ablation with L-alpha-aminoadipate, and static co-cultures—establish correlations but struggle with causality and physiological relevance. The new generation is more surgical. SPEAC-seq, or systematic perturbation of encapsulated associated cells followed by sequencing, places single NF-κB-reporter astrocytes and CRISPR-edited microglia into oil droplets, lets them communicate, then sorts activated pairs and sequences the guide RNAs to discover which microglial genes drive astrocyte inflammation. RABID-seq uses a barcoded, astrocyte-targeted rabies virus to map the in vivo astrocyte interaction network at single-cell resolution, and has already revealed immunosuppressive astrocyte subtypes interacting with glioblastoma. Human-relevant platforms are advancing too: 3D bioprinted neural tissues, vascularized brain organoids containing human microglia implanted into mouse brains, and microfluidic co-culture devices that model neuroinflammatory interactions using human induced pluripotent stem cell derivatives.

The bigger picture emerging from this synthesis is that astrocytes and microglia are not independent responders but interconnected cellular partners whose molecular dialogue shapes the central nervous system from embryogenesis to aging. Some glial responses traditionally interpreted as cell-autonomous may instead emerge from coordinated interactions between the two cell types, and inflammatory signaling between them can even promote epigenetic remodeling of astrocytes, altering their metabolic support functions. The authors argue that future research must move beyond studying each cell in isolation and instead define how their bidirectional interactions are regionally organized, temporally regulated, and dynamically modified across physiological and pathological states. Only then, they suggest, can therapies be designed to modulate neuroinflammation without compromising the homeostatic functions of glial networks—a balance that may prove decisive for treating Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, epilepsy, and traumatic brain injury.

Subject of Research: Astrocyte–microglia crosstalk in central nervous system development, homeostasis, injury, and disease

Article Title: “Stand by me”: astrocyte–microglia crosstalk in central nervous system development, homeostasis, injury, and disease

Article References: Ramos, A. J., & Villarreal, A. (2026). “Stand by me”: astrocyte–microglia crosstalk in central nervous system development, homeostasis, injury, and disease. Frontiers in Network Physiology, 6, Article 1895622. https://doi.org/10.3389/fnetp.2026.1895622

Image Credits: AI Generated

DOI: 10.3389/fnetp.2026.1895622

Keywords: astrocytes, microglia, glial crosstalk, neuroinflammation, synaptic pruning, complement cascade, neurodegeneration, blood-brain barrier, reactive gliosis, brain development, NF-kB signaling, single-cell sequencing